Flanigan v. Rheumatology Diagnostics Laboratory CA2/5

CourtCalifornia Court of Appeal
DecidedJune 20, 2024
DocketB318831
StatusUnpublished

This text of Flanigan v. Rheumatology Diagnostics Laboratory CA2/5 (Flanigan v. Rheumatology Diagnostics Laboratory CA2/5) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Flanigan v. Rheumatology Diagnostics Laboratory CA2/5, (Cal. Ct. App. 2024).

Opinion

Filed 6/20/24 Flanigan v. Rheumatology Diagnostics Laboratory CA2/5 NOT TO BE PUBLISHED IN THE OFFICIAL REPORTS

California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION FIVE

MATTHEW FLANIGAN, B318831 c/w B320941

Plaintiff and Respondent, (Los Angeles County Super. Ct. No. BC688804) v.

RHEUMATOLOGY DIAGNOSTICS LABORATORY, INC.,

Defendant and Appellant.

APPEAL from a judgment and postjudgment order of the Superior Court of Los Angeles County, Terry A. Green, Judge. Reversed and remanded with directions. Schlichter, Shonack & Keeton, Jamie L. Keeton and Joel L. Williams for Defendant and Appellant. Law Offices of Edward Y. Lee and Edward Y. Lee for Plaintiff and Respondent.

___________________________ Plaintiff Matthew Flanigan (Flanigan) was employed as the director of IT for defendant Rheumatology Diagnostics Laboratory, Inc. (RDL). Shareholders (former RDL employees) brought a derivative action against RDL and its management. To investigate and defend against those claims, RDL’s CEO and attorney spoke behind closed doors with Flanigan, who had previously reported what he believed to be illegal conduct by another RDL employee and who raised the issue again during the meeting. Flanigan then disclosed communications from this meeting to the plaintiffs in the shareholder action and their attorneys, and signed a declaration to support them in their derivative suit. Around the same time, Flanigan refused to sign a declaration (which contained information he believed to be false) to aid RDL’s management in defending against the shareholder suit. RDL placed Flanigan on leave upon learning he had signed a declaration to support the derivative action, and ultimately terminated him. Flanigan sued RDL for retaliation under Labor Code section 1102.5. The matter proceeded to trial by jury, and judgment was entered in Flanigan’s favor. RDL appeals from that judgment arguing that Flanigan’s retaliation claim fails as a matter of law. Labor Code section 1102.5 prohibits employers from retaliating against employees for engaging in protected activities, such as reporting illegal conduct to an employee’s superiors or refusing to participate in an illegal activity. (Lab. Code, § 1102.5, subds. (b), (c).) Subdivision (g) of the same section contains an important carveout: The section does not protect against “actions by employers against employees who violate[] the confidentiality of the [attorney]-client privilege [(Evid. Code, § 950 et seq.)].”

2 (Lab. Code, § 1102.5, subd. (g).) The attorney-client privilege, in turn, is subject to an exception—the crime-fraud exception (Evid. Code, § 956)—under which the privilege does not exist “if the services of the lawyer were sought or obtained to enable or aid anyone to commit or plan to commit a crime or a fraud.” (Ibid.) The attorney-client privilege (Evid. Code, § 950 et seq.) and the crime-fraud exception thereto (Evid. Code, § 956) typically arise in the context of discovery disputes (e.g., BP Alaska Exploration, Inc. v. Superior Court (1988) 199 Cal.App.3d 1240 (BP Alaska); People v. Superior Court (Bauman & Rose) (1995) 37 Cal.App.4th 1757 (Bauman & Rose); State Farm Fire &Casualty Co. v. Superior Court (1997) 54 Cal.App.4th 625 (State Farm); Kerner v. Superior Court (2012) 206 Cal.App.4th 84); no California court has examined either doctrine in the context of a claim for retaliation under Labor Code section 1102.5. We are tasked with determining whether, in view of these statutes and the competing interests they further, Flanigan’s lawsuit for retaliation (1) is barred under Labor Code section 1102.5, subdivision (g) because he disclosed RDL’s attorney-client privileged communications to third parties, or (2) is not barred because, under the crime-fraud exception, RDL’s request that Flanigan sign a declaration he believed to be false stripped the disclosed communications of any attorney-client privilege. Applying the statutes involved, we conclude that the disclosed communications are not subject to crime-fraud exception, and that the employer’s interest in terminating employment of those who violate the attorney-client privilege prevails under these circumstances. Because Flanigan disclosed RDL’s privileged communications, he is not entitled to the protections afforded by Labor Code section 1102.5 (Lab. Code,

3 § 1102.5, subd. (g)). Accordingly, we reverse the judgment in Flanigan’s favor and vacate his award of attorney fees. FACTS AND PROCEDURAL BACKGROUND I. Pleadings On January 5, 2018, Flanigan filed a complaint against RDL for violation of Labor Code section 1102.5, retaliation under California Fair Employment and Housing Act (FEHA), and wrongful termination in violation of public policy. Flanigan’s complaint alleges: In April 2017, he discovered that RDL employee Kristine Azarraga (Azarraga) had plugged a thumb drive into the RDL network and imported copies of her former employer’s standard operating procedures (SOPs) that included billing data, patient demographics, patient test results, and other proprietary information. Flanigan believed that this conduct violated the Health Insurance Portability and Accountability Act of 1996 (HIPAA), and reported it to RDL’s senior management. On August 15, 2017, former RDL employees Samuel Morris (Morris) and Richard Kazdan (Kazdan)—collectively, “shareholder plaintiffs”—filed a lawsuit against RDL’s CEO Allan Metzger (Metzger), Azarraga, and a doctor employed by RDL (collectively, “derivative defendants”) for breach of fiduciary duty based on mismanagement of the business and misappropriation of corporate assets. RDL was named as a nominal defendant. After being served with the complaint, derivative defendants sought Flanigan’s assistance to prepare a false declaration to defend against the shareholder action. Flanigan declined to perjure himself and instead signed a declaration to support shareholder plaintiffs in their ex parte motion—filed

4 August 29, 2017—to enjoin the alleged mismanagement by derivative defendants. Immediately after receiving the ex parte motion containing Flanigan’s declaration, Metzger placed Flanigan on investigatory leave. Flanigan’s employment was then terminated on September 12, 2017. RDL terminated Flanigan for reporting Azarraga’s HIPAA violation and/or for refusing to commit an illegal act (perjury). II. Declarations A. Declaration Flanigan Refused to Sign for Derivative Defendants The declaration Flanigan refused to sign is exhibit one to his complaint. It is dated August 28, 2017, and states: “The complaint contains allegations related to RDL’s protection[] of its trade secrets and intellectual property. It alleges . . . [Azarraga] ‘unlawfully accessed, downloaded, and printed [RDL’s] entire SOP library.’ I am not aware of any evidence that would support this allegation. Similarly, the complaint alleges . . . [Azarraga] had used a thumb drive to upload SOPs from her previous employer into the RDL server.’ I am not aware of evidence that would support that allegation either.” B. Declaration Flanigan Signed to Support Shareholder Plaintiffs Attached as exhibit two to Flanigan’s complaint is the declaration he signed in support of the shareholder plaintiffs, also dated August 28, 2017. The declaration states that Flanigan notified RDL’s senior management in April 2017 that Azarraga had used a thumb drive to view proprietary SOPs from her prior employer. The declaration also discloses communications between Flanigan, Metzger, and RDL’s attorney at their August 18, 2017 meeting as follows: Metzger called Flanigan into

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Zolin
491 U.S. 554 (Supreme Court, 1989)
Melendrez v. Superior Court
215 Cal. App. 4th 1343 (California Court of Appeal, 2013)
Foley v. Interactive Data Corp.
765 P.2d 373 (California Supreme Court, 1988)
Stevenson v. Superior Court
941 P.2d 1157 (California Supreme Court, 1997)
Fowler v. Varian Associates, Inc.
196 Cal. App. 3d 34 (California Court of Appeal, 1987)
BP Alaska Exploration, Inc. v. Superior Court
199 Cal. App. 3d 1240 (California Court of Appeal, 1988)
HUONG QUE, INC. v. Luu
58 Cal. Rptr. 3d 527 (California Court of Appeal, 2007)
State Compensation Insurance Fund v. Superior Court
111 Cal. Rptr. 2d 284 (California Court of Appeal, 2001)
State Farm Fire & Cas. Co. v. Superior Court of L.A. Cty.
54 Cal. App. 4th 625 (California Court of Appeal, 1997)
Stokes v. Dole Nut Co.
41 Cal. App. 4th 285 (California Court of Appeal, 1995)
People v. Superior Court (Bauman & Rose)
37 Cal. App. 4th 1757 (California Court of Appeal, 1995)
Chubb & Son v. Superior Court
228 Cal. App. 4th 1094 (California Court of Appeal, 2014)
Edwards Wildman Palmer LLP v. Superior Court
231 Cal. App. 4th 1214 (California Court of Appeal, 2014)
City of Moorpark v. Superior Court
959 P.2d 752 (California Supreme Court, 1998)
Costco Wholesale Corp. v. Superior Court
219 P.3d 736 (California Supreme Court, 2009)
Kerner v. Superior Court
206 Cal. App. 4th 84 (California Court of Appeal, 2012)
Dutra v. Mercy Medical Center Mt. Shasta
209 Cal. App. 4th 750 (California Court of Appeal, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Flanigan v. Rheumatology Diagnostics Laboratory CA2/5, Counsel Stack Legal Research, https://law.counselstack.com/opinion/flanigan-v-rheumatology-diagnostics-laboratory-ca25-calctapp-2024.